Organon (OGN) Return on Assets Growth (3y) (2024 - 2026)
Organon (OGN) Return on Assets Growth (3y) (2024 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Gsk |
92,134,969.93 Bn |
92,134,964.97 Bn |
7.76 Bn |
| 2 |
Eli Lilly |
1,027.45 Bn |
1,022.17 Bn |
16.22 Bn |
| 3 |
Johnson & Johnson |
559.08 Bn |
537.03 Bn |
15.96 Bn |
| 4 |
AbbVie |
394.75 Bn |
385.40 Bn |
10.78 Bn |
| 5 |
Merck |
295.12 Bn |
289.47 Bn |
12.09 Bn |
| 6 |
Amgen |
186.65 Bn |
174.61 Bn |
5.87 Bn |
| 7 |
Gilead Sciences |
159.22 Bn |
151.50 Bn |
5.52 Bn |
| 8 |
Pfizer |
146.00 Bn |
133.23 Bn |
-1.21 Bn |
| 9 |
Bristol Myers Squibb |
113.22 Bn |
102.77 Bn |
8.07 Bn |
| 10 |
Organon |
3.49 Bn |
2.37 Bn |
783.00 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
0.00 |
| Mar 31, 2025 |
0.00 |
| Sep 30, 2024 |
0.00 |
| Jun 30, 2024 |
0.00 |
| Mar 31, 2024 |
0.00 |
